FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Search
Boehringer Ingelheim announces appointments
Boehringer Ingelheim announces appointments
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
Lothar Halmer
Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA
Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Ileitis prevention vaccination Lawsonia intracellularis pig
Cause, impact and prevention: Learn the essentials about Ileitis
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
New biomass power plant Ingelheim
Boehringer Ingelheim produces its own green energy
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
We are Global Top Employer 2024
Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Finding the right inhaler for you
Living with a chronic respiratory disease can make life complicated. This discussion guide can be used to help start a conversation with a healthcare professional about inhaler choice.
New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide